Related Experiment Video
Updated: Jun 2, 2025
Establishment of a Simple and Effective Rat Model for Intraoperative Parathyroid Gland Imaging
Published on: August 17, 2022
Chapter 9: Indications for the treatment of primary hyperparathyroidism
Samuel Frey1, Helena Mosbah2, Gianluca Donatini3
1Institut du thorax, chirurgie cancérologique, digestive et endocrinienne, institut des maladies de l'appareil digestif, CNRS, Inserm, CHU de Nantes, Nantes université, 44000 Nantes, France.
Treatment for primary hyperparathyroidism varies based on disease severity, patient specifics, and risk-benefit analysis of options like surgery, local destruction, or medication. This review outlines current treatment indications.
Area of Science:
- Endocrinology
- Surgical Oncology
- Pharmacology
Background:
- Primary hyperparathyroidism (PHPT) is a common endocrine disorder.
- Treatment decisions for PHPT are complex and multifactorial.
- Untreated PHPT can lead to significant complications.
Purpose of the Study:
- To summarize the current indications for treating primary hyperparathyroidism.
- To provide a comprehensive overview based on recent international literature.
Main Methods:
- Systematic review of international literature up to December 31st, 2023.
- Analysis of factors influencing therapeutic choices in PHPT management.
Main Results:
- Treatment selection depends on disease severity, patient condition, and risk-benefit assessment.
- Therapeutic options include surgery, local destruction, and pharmacotherapy.
Conclusions:
- Evidence-based guidelines are crucial for optimal PHPT management.
- Personalized treatment strategies are essential for effective patient care.
More Related Videos
Related Concept Videos
00:59The Parathyroid Glands
Oxyphil cells, whose functions remain elusive, emerge during late puberty, adding a layer of complexity to the parathyroid gland's intricacies. In contrast, principal parathyroid cells undertake a vital role by...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:17Hormones and Bone Tissue
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
01:21Skeleton and Calcium Homeostasis
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...